Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Oct 14, 2022
- FUJIFILM Toyama Chemical discontinues development of “Avigan® Tablet” anti-influenza drug as a treatment for COVID-19 (Fujifilm)
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan (Fujifilm)
- Mar 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product (Fujifilm) - Mar 11, 2022
- Fujifilm to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients (Fujifilm)
- Sep 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream (Fujifilm)
- Aug 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan
- Jun 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors - Apr 21, 2021
- Fujifilm announces the Start of a New Phase III Clinical Trial of Anti-influenza Drug Avigan® Tablet in Japan, Targeting COVID-19 Patients (FUJIFILM Corporation)
- Oct 22, 2020
- Fujifilm Partners with Chinese Pharmaceutical Company Carelink in Deploying Anti-influenza Drug Avigan® Tablets in China (FUJIFILM Corporation)
- Oct 16, 2020
- Fujifilm Filed an Application for Partial Changes to the Manufacturing and Marketing Approval Matters of Anti-Influenza Drug Avigan® Tablet in Japan to Include Additional Indication for COVID-19 (FUJIFILM Corporation)